GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

GenSight Biologics Reports Cash Position as of September 30, 2023, and Provides Business Update

GenSight Biologics Reports Interim Financial Results for the First Half of 2023

GenSight Biologics obtains funding of €10 million from Sofinnova Partners, Invus and UPMC Enterprises

GenSight Biologics Provides Financial and Operational Update

GenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update

GenSight Biologics Reports Full Year 2022 Consolidated Financial Results

GenSight Biologics Announces its 2023 Financial Calendar

GenSight Biologics to Present at Upcoming Investor Conferences

GenSight Biologics secures €12 Million financing through a premium convertible notes issuance to an institutional investor and provides business update